Transgene Sa Stock Cash Per Share
| TNG Stock | EUR 0.73 0.01 1.35% |
Transgene SA fundamentals help investors to digest information that contributes to Transgene's financial success or failures. It also enables traders to predict the movement of Transgene Stock. The fundamental analysis module provides a way to measure Transgene's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Transgene stock.
Transgene |
Transgene SA Company Cash Per Share Analysis
Transgene's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current Transgene Cash Per Share | 0.27 X |
Most of Transgene's fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Transgene SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
In accordance with the recently published financial statements, Transgene SA has a Cash Per Share of 0.27 times. This is 93.79% lower than that of the Healthcare sector and 93.76% lower than that of the Biotechnology industry. The cash per share for all France stocks is 94.61% higher than that of the company.
Transgene Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Transgene's direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Transgene could also be used in its relative valuation, which is a method of valuing Transgene by comparing valuation metrics of similar companies.Transgene is currently under evaluation in cash per share category among its peers.
Transgene Fundamentals
| Return On Equity | -0.36 | |||
| Return On Asset | -0.16 | |||
| Profit Margin | (1.27) % | |||
| Operating Margin | (1.39) % | |||
| Current Valuation | 144.73 M | |||
| Shares Outstanding | 100.2 M | |||
| Shares Owned By Institutions | 1.70 % | |||
| Price To Earning | 18.08 X | |||
| Price To Book | 3.39 X | |||
| Price To Sales | 10.07 X | |||
| Revenue | 9.99 M | |||
| Gross Profit | (15.87 M) | |||
| EBITDA | (16.55 M) | |||
| Net Income | (19.54 M) | |||
| Cash And Equivalents | 16.9 M | |||
| Cash Per Share | 0.27 X | |||
| Debt To Equity | 162.30 % | |||
| Current Ratio | 1.52 X | |||
| Book Value Per Share | 0.55 X | |||
| Cash Flow From Operations | (31.94 M) | |||
| Earnings Per Share | (0.23) X | |||
| Target Price | 4.3 | |||
| Number Of Employees | 143 | |||
| Beta | 0.79 | |||
| Market Capitalization | 205.42 M | |||
| Total Asset | 101.84 M | |||
| Retained Earnings | (538 M) | |||
| Working Capital | 24 M | |||
| Current Asset | 51 M | |||
| Current Liabilities | 27 M | |||
| Z Score | -7.0 | |||
| Net Asset | 101.84 M |
About Transgene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Transgene SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Transgene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Transgene SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Transgene Stock
Transgene financial ratios help investors to determine whether Transgene Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Transgene with respect to the benefits of owning Transgene security.